Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of pegylated interferon alpha-2 injection for herpes zoster
CTR20223443Phase 2Active
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2a in herpes zoster (HZ), sponsored by Beijing Kawin Technology Share-Holding Co., Ltd.. Started May 2023; status: active.
02
Drugs
peginterferon alfa-2a
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20223443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223443.